We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Resverlogix Completes Enrollment in ASSURE Trial

Resverlogix Completes Enrollment in ASSURE Trial

Resverlogix Completes Enrollment in ASSURE Trial

Resverlogix Completes Enrollment in ASSURE Trial

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Resverlogix Completes Enrollment in ASSURE Trial"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Resverlogix Corp. has announced that it has completed enrollment in ASSURE, a Phase 2b clinical trial targeting high-risk cardiovascular disease patients.

ASSURE will evaluate the ability of RVX-208, Resverlogix's BET protein inhibitor, to regress atherosclerotic disease versus placebo using intravascular ultrasound (IVUS) technology in patients with coronary artery disease (CAD).

"Completing enrollment of the ASSURE clinical trial marks another major milestone for Resverlogix as we aim to demonstrate the efficacy of RVX-208 in atherosclerotic plague regression," stated Donald McCaffrey, president and chief executive officer of Resverlogix.

McCaffrey continued, "RVX-208 stimulates production of ApoA-I, increasing the functional HDL particles required for reverse cholesterol transport. We expect to announce top-line data from ASSURE in H1 2013."

ASSURE is a 26-week, multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial led by the Cleveland Clinic.

The primary trial endpoint will be measurement of atheroma volume reduction from baseline to 26 weeks measured by IVUS.

Secondary objectives for ASSURE are evaluating the safety and tolerability of RVX-208 and effects of RVX-208 on HDL and non-HDL lipid parameters.

Using IVUS data, we will also assess changes in plaque stability, an important factor affecting risk of myocardial infarction.